Logo image of SGMT

SAGIMET BIOSCIENCES INC-A (SGMT) Stock Fundamental Analysis

NASDAQ:SGMT - Nasdaq - US7867001049 - Common Stock - Currency: USD

4.4  +0.34 (+8.37%)

After market: 4.3978 0 (-0.05%)

Fundamental Rating

4

SGMT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. SGMT has a great financial health rating, but its profitability evaluates not so good. SGMT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SGMT has reported negative net income.
SGMT had a negative operating cash flow in the past year.
SGMT had negative earnings in each of the past 5 years.
SGMT had a negative operating cash flow in each of the past 5 years.
SGMT Yearly Net Income VS EBIT VS OCF VS FCFSGMT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

SGMT has a Return On Assets of -15.95%. This is amongst the best in the industry. SGMT outperforms 81.95% of its industry peers.
With an excellent Return On Equity value of -16.33%, SGMT belongs to the best of the industry, outperforming 88.14% of the companies in the same industry.
Industry RankSector Rank
ROA -15.95%
ROE -16.33%
ROIC N/A
ROA(3y)-54.19%
ROA(5y)-61.37%
ROE(3y)-61.4%
ROE(5y)-72.43%
ROIC(3y)N/A
ROIC(5y)N/A
SGMT Yearly ROA, ROE, ROICSGMT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

SGMT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGMT Yearly Profit, Operating, Gross MarginsSGMT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -500 -1K -1.5K

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for SGMT has been increased compared to 1 year ago.
SGMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SGMT Yearly Shares OutstandingSGMT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M 20M
SGMT Yearly Total Debt VS Total AssetsSGMT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 19.02 indicates that SGMT is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 19.02, SGMT belongs to the best of the industry, outperforming 92.04% of the companies in the same industry.
There is no outstanding debt for SGMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.02
ROIC/WACCN/A
WACCN/A
SGMT Yearly LT Debt VS Equity VS FCFSGMT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 38.41 indicates that SGMT has no problem at all paying its short term obligations.
SGMT has a Current ratio of 38.41. This is amongst the best in the industry. SGMT outperforms 98.76% of its industry peers.
SGMT has a Quick Ratio of 38.41. This indicates that SGMT is financially healthy and has no problem in meeting its short term obligations.
SGMT has a better Quick ratio (38.41) than 98.76% of its industry peers.
Industry RankSector Rank
Current Ratio 38.41
Quick Ratio 38.41
SGMT Yearly Current Assets VS Current LiabilitesSGMT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

3

3. Growth

3.1 Past

SGMT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -87.67%.
EPS 1Y (TTM)-87.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 11.61% on average over the next years. This is quite good.
The Revenue is expected to grow by 124.02% on average over the next years. This is a very strong growth
EPS Next Y90.25%
EPS Next 2Y33.1%
EPS Next 3Y19.51%
EPS Next 5Y11.61%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y124.02%

3.3 Evolution

SGMT Yearly Revenue VS EstimatesSGMT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SGMT Yearly EPS VS EstimatesSGMT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SGMT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SGMT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGMT Price Earnings VS Forward Price EarningsSGMT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGMT Per share dataSGMT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as SGMT's earnings are expected to grow with 19.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.1%
EPS Next 3Y19.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SGMT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAGIMET BIOSCIENCES INC-A

NASDAQ:SGMT (1/31/2025, 8:00:02 PM)

After market: 4.3978 0 (-0.05%)

4.4

+0.34 (+8.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners70.15%
Inst Owner Change-0.15%
Ins Owners1.07%
Ins Owner Change0%
Market Cap141.68M
Analysts83.08
Price Target34.1 (675%)
Short Float %15.78%
Short Ratio4.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.8%
Min EPS beat(2)-8.35%
Max EPS beat(2)25.95%
EPS beat(4)2
Avg EPS beat(4)5.85%
Min EPS beat(4)-37.49%
Max EPS beat(4)43.27%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.46%
PT rev (3m)2.54%
EPS NQ rev (1m)3.23%
EPS NQ rev (3m)10.72%
EPS NY rev (1m)0.21%
EPS NY rev (3m)-3.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 70.84
P/FCF N/A
P/OCF N/A
P/B 0.83
P/tB 0.83
EV/EBITDA N/A
EPS(TTM)-1.71
EYN/A
EPS(NY)-3.76
Fwd EYN/A
FCF(TTM)-1.2
FCFYN/A
OCF(TTM)-1.2
OCFYN/A
SpS0.06
BVpS5.3
TBVpS5.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.95%
ROE -16.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.19%
ROA(5y)-61.37%
ROE(3y)-61.4%
ROE(5y)-72.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 38.41
Quick Ratio 38.41
Altman-Z 19.02
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
EPS Next Y90.25%
EPS Next 2Y33.1%
EPS Next 3Y19.51%
EPS Next 5Y11.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y124.02%
EBIT growth 1Y1.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-69.83%
EBIT Next 3Y-94.95%
EBIT Next 5YN/A
FCF growth 1Y2.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.96%
OCF growth 3YN/A
OCF growth 5YN/A